# Nefecon and Ambrisentan in IgA Nephropathy

> **NCT07030894** · PHASE4 · RECRUITING · sponsor: **The First Hospital of Jilin University** · enrollment: 129 (estimated)

## Conditions studied

- IgA Nephropathy
- Chronic Kidney Disease
- Proteinuria

## Interventions

- **DRUG:** "Nefecon®","Ambrisentan"

## Key facts

- **NCT ID:** NCT07030894
- **Lead sponsor:** The First Hospital of Jilin University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 129 (ESTIMATED)
- **Last updated:** 2025-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07030894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07030894, "Nefecon and Ambrisentan in IgA Nephropathy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07030894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*